Literature DB >> 30305545

[Guidelines based on scientific evidence for the application of platelet transfusion concentrates].

Akiyoshi Takami1.   

Abstract

Platelet transfusion concentrates are commonly used to prevent and treat bleeding due to thrombocytopenia and abnormal platelet function. Although these concentrates are indispensable while safely conducting anticancer chemotherapy and surgery, their use may cause certain adverse effects, including fever, urticaria, anaphylaxis, and transfusion-related acute lung injury. In addition, repeated platelet transfusions may induce allogeneic antibodies, possibly resulting in platelet transfusion refractoriness (PTR). Intrinsically, the use of platelet transfusion concentrates should be carefully administered and reserved to a minimum. This chapter introduces the guidelines based on scientific evidence for the therapeutic use of platelet transfusion concentrates, which The Japan Society of Transfusion Medicine and Cell Therapy recently established.

Entities:  

Keywords:  Acute leukemia; Hematopoietic failure; Platelet transfusion trigger value; Thrombocytopenia

Mesh:

Year:  2018        PMID: 30305545     DOI: 10.11406/rinketsu.59.2349

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  3 in total

1.  Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.

Authors:  Ying Liu; Yufan Zhang; Dawei Chen; Yongshui Fu
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 2.  Bleeding disorders in implant dentistry: a narrative review and a treatment guide.

Authors:  Paul Römer; Diana Heimes; Andreas Pabst; Philipp Becker; Daniel G E Thiem; Peer W Kämmerer
Journal:  Int J Implant Dent       Date:  2022-04-16

3.  An infantile case of hereditary folate malabsorption with sudden development of pulmonary hemorrhage: a case report.

Authors:  Yukari Sakurai; Naohisa Toriumi; Takeo Sarashina; Toru Ishioka; Marino Nagata; Hiroya Kobayashi; Hiroshi Azuma
Journal:  J Med Case Rep       Date:  2022-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.